Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$139.01 USD

139.01
946,947

+0.87 (0.63%)

Updated Apr 30, 2024 04:00 PM ET

After-Market: $139.04 +0.03 (0.02%) 5:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (171 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

CVS-Aetna Deal Leading a Wave of Change in Hospital Sector

Increased consolidation is being witnessed in the hospital sector as a defense against invasion by new comers.

    Company News For Dec 7, 2017

    Companies In The News are: PLAY,OXM,HRB,DVA,UNH

      DaVita (DVA) Surges: Stock Moves 13.6% Higher

      DaVita (DVA) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes

        UnitedHealth to Buy DaVita Medical, Expands Optum Business

        UnitedHealth's (UNH) intention to buy DaVita Medical reflects its continuous effort to build up a vertically integrated business model

          Benjamin Rains headshot

          UnitedHealth Continues Healthcare Shakeup With DaVita Deal

          On Wednesday, only a few days after the CVS (CVS) and Aetna (AET) deal helped shine a light on the quickly changing healthcare industry, UnitedHealth Group (UNH) announced that it will buy a unit of DaVita Inc. (DVA) for nearly $5 billion.

            New Strong Sell Stocks for November 10th

            Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

              What's in the Cards for DaVita (DVA) Stock in Q3 Earnings?

              DaVita's (DVA) ongoing cost inflation might weigh on its margins in Q3. However, the Kidney Care business raises hope with steady investments in capital-efficient technologies.

                Should Value Investors Consider DaVita Inc. (DVA) Stock?

                Let's put DaVita Inc. (DVA) stock into this equation and find out if it is a good choice for value-oriented investors right now.

                  DaVita HealthCare (DVA) Down 9.1% Since Earnings Report: Can It Rebound?

                  DaVita HealthCare (DVA) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    C. R. Bard's (BCR) LUTONIX 035 Gets FDA Pre-Market Approval

                    The early market acceptance of the LUTONIX platform has been impressive and C. R. Bard (BCR) is likely to witness an expanded adoption of this technology as the market continues to mature.

                      DaVita (DVA) Beats Earnings and Revenue Estimates in Q2

                      DaVita's (DVA) stable performance across its businesses was the key highlight of the second quarter.

                        DaVita Medical Group Buys Dr. Rahn Shaw Practices in Orlando

                        DaVita Inc. (DVA) recently acquired Dr. Rahn Shaw's practices, Park Avenue Medical, Inc. and Winter Park Health Center, Inc., each located in Orlando.

                          DaVita Banks on Acquisitions, Escalating Expenses a Concern

                          On Jun 23, we issued an updated research report on Denver, CO-based DaVita HealthCare Partners Inc. (DVA).

                            Is DaVita a Suitable Stock for Value Investors?

                            Let's focus on DaVita Inc. (DVA) stock and find out if it is a good choice for value-oriented investors right now or not.

                              DaVita (DVA) Rolls Out Alliance Site Network for CKD Trial

                              DaVita Inc (DVA), through its subsidiary DaVita Clinical Research (DCR), recently announced the expansion of its research services to include Alliance Site Network.

                                DaVita (DVA): What's in the Cards this Earnings Season?

                                DaVita HealthCare Partners Inc (DVA), is expected to report first-quarter fiscal 2017 results on May 2, after market close.

                                  Why Is DaVita (DVA) Up 4.8% Since the Last Earnings Report?

                                  DaVita (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                    DaVita (DVA) Ties Up with Cigna Arm, Expands in Los Angeles

                                    DaVita HealthCare Partners Inc. (DVA), a leading provider of dialysis services, announced that HealthCare Partners, a unit within its medical group, has entered into a strategic partnership with Cigna, a global health insurance service company.

                                      DaVita (DVA) Earnings Beat Estimates, Revenues Lag in Q4

                                      DaVita Inc. (DVA) reported fourth-quarter 2016 adjusted operating earnings of 98 cents per share that surpassed the Zacks Consensus Estimate of 91 cents.

                                        ITT Inc. (ITT) Q4 Earnings: What's in Store for the Stock?

                                        ITT Inc. (ITT) is slated to report fourth-quarter 2016 results before the opening bell on Feb 14.

                                          Can Allscripts (MDRX) Surprise Investors in Q4 Earnings?

                                          Allscripts Healthcare Solutions Inc. (MDRX) is scheduled to release fourth-quarter 2016 results on Feb 16.

                                            Can Nutrisystem (NTRI) Surprise Investors in Q4 Earnings?

                                            Nutrisystem Inc. (NTRI) is scheduled to release fourth-quarter 2016 results on Feb 27.

                                              Ecolab (ECL): What's in the Cards this Earnings Season?

                                              St. Paul, MN-based Ecolab Inc. (ECL), a leading provider of water, hygiene and energy technologies and services, is expected to report fourth-quarter 2016 results on Feb 21.

                                                DENTSPLY (XRAY) Q4 Earnings: Is Disappointment in Store?

                                                York, PA-based DENTSPLY Sirona Inc. (XRAY), a dental solutions company, is expected to report fourth-quarter 2016 results on Feb 10.

                                                  Will Q4 Earnings Hold a Surprise for DaVita (DVA) Stock?

                                                  DaVita HealthCare Partners Inc. (DVA) is set to report fourth-quarter 2016 results after market close on Feb 9.